Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 617

1.
2.

MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.

Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G, Bertorelle R, Bartolini S, Calbucci F, Andreoli A, Frezza G, Leonardi M, Spagnolli F, Ermani M.

J Clin Oncol. 2008 May 1;26(13):2192-7. doi: 10.1200/JCO.2007.14.8163.

PMID:
18445844
3.

IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry.

Yang P, Zhang W, Wang Y, Peng X, Chen B, Qiu X, Li G, Li S, Wu C, Yao K, Li W, Yan W, Li J, You Y, Chen CC, Jiang T.

Oncotarget. 2015 Dec 1;6(38):40896-906. doi: 10.18632/oncotarget.5683.

4.

A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas.

Arita H, Yamasaki K, Matsushita Y, Nakamura T, Shimokawa A, Takami H, Tanaka S, Mukasa A, Shirahata M, Shimizu S, Suzuki K, Saito K, Kobayashi K, Higuchi F, Uzuka T, Otani R, Tamura K, Sumita K, Ohno M, Miyakita Y, Kagawa N, Hashimoto N, Hatae R, Yoshimoto K, Shinojima N, Nakamura H, Kanemura Y, Okita Y, Kinoshita M, Ishibashi K, Shofuda T, Kodama Y, Mori K, Tomogane Y, Fukai J, Fujita K, Terakawa Y, Tsuyuguchi N, Moriuchi S, Nonaka M, Suzuki H, Shibuya M, Maehara T, Saito N, Nagane M, Kawahara N, Ueki K, Yoshimine T, Miyaoka E, Nishikawa R, Komori T, Narita Y, Ichimura K.

Acta Neuropathol Commun. 2016 Aug 8;4(1):79. doi: 10.1186/s40478-016-0351-2.

5.

The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy.

Millward CP, Brodbelt AR, Haylock B, Zakaria R, Baborie A, Crooks D, Husband D, Shenoy A, Wong H, Jenkinson MD.

Acta Neurochir (Wien). 2016 Oct;158(10):1943-53. doi: 10.1007/s00701-016-2928-8. Epub 2016 Aug 15.

PMID:
27526690
6.

MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.

Donson AM, Addo-Yobo SO, Handler MH, Gore L, Foreman NK.

Pediatr Blood Cancer. 2007 Apr;48(4):403-7.

PMID:
16609952
7.

IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma.

SongTao Q, Lei Y, Si G, YanQing D, HuiXia H, XueLin Z, LanXiao W, Fei Y.

Cancer Sci. 2012 Feb;103(2):269-73. doi: 10.1111/j.1349-7006.2011.02134.x. Epub 2011 Nov 28.

8.

IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy.

Minniti G, Scaringi C, Arcella A, Lanzetta G, Di Stefano D, Scarpino S, Bozzao A, Pace A, Villani V, Salvati M, Esposito V, Giangaspero F, Enrici RM.

J Neurooncol. 2014 Jun;118(2):377-383. doi: 10.1007/s11060-014-1443-0. Epub 2014 Apr 20.

PMID:
24748470
9.

MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.

Kim YS, Kim SH, Cho J, Kim JW, Chang JH, Kim DS, Lee KS, Suh CO.

Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):661-7. doi: 10.1016/j.ijrobp.2011.12.086. Epub 2012 Mar 11.

PMID:
22414280
10.

MGMT inactivation and clinical response in newly diagnosed GBM patients treated with Gliadel.

Grossman R, Burger P, Soudry E, Tyler B, Chaichana KL, Weingart J, Olivi A, Gallia GL, Sidransky D, Quiñones-Hinojosa A, Ye X, Brem H.

J Clin Neurosci. 2015 Dec;22(12):1938-42. doi: 10.1016/j.jocn.2015.07.003. Epub 2015 Aug 4.

PMID:
26249244
11.

Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.

Barbagallo GM, Paratore S, Caltabiano R, Palmucci S, Parra HS, Privitera G, Motta F, Lanzafame S, Scaglione G, Longo A, Albanese V, Certo F.

Neurosurg Focus. 2014 Dec;37(6):E4. doi: 10.3171/2014.9.FOCUS14502.

PMID:
25434389
12.

MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.

Weller M, Tabatabai G, Kästner B, Felsberg J, Steinbach JP, Wick A, Schnell O, Hau P, Herrlinger U, Sabel MC, Wirsching HG, Ketter R, Bähr O, Platten M, Tonn JC, Schlegel U, Marosi C, Goldbrunner R, Stupp R, Homicsko K, Pichler J, Nikkhah G, Meixensberger J, Vajkoczy P, Kollias S, Hüsing J, Reifenberger G, Wick W; DIRECTOR Study Group.

Clin Cancer Res. 2015 May 1;21(9):2057-64. doi: 10.1158/1078-0432.CCR-14-2737. Epub 2015 Feb 5.

13.

DGKI methylation status modulates the prognostic value of MGMT in glioblastoma patients treated with combined radio-chemotherapy with temozolomide.

Etcheverry A, Aubry M, Idbaih A, Vauleon E, Marie Y, Menei P, Boniface R, Figarella-Branger D, Karayan-Tapon L, Quillien V, Sanson M, de Tayrac M, Delattre JY, Mosser J.

PLoS One. 2014 Sep 18;9(9):e104455. doi: 10.1371/journal.pone.0104455. eCollection 2014.

14.

Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.

Nguyen HN, Lie A, Li T, Chowdhury R, Liu F, Ozer B, Wei B, Green RM, Ellingson BM, Wang HJ, Elashoff R, Liau LM, Yong WH, Nghiemphu PL, Cloughesy T, Lai A.

Neuro Oncol. 2017 Mar 1;19(3):394-404. doi: 10.1093/neuonc/now189.

15.

Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells.

Taspinar M, Ilgaz S, Ozdemir M, Ozkan T, Oztuna D, Canpinar H, Rey JA, Sunguroğlu A, Castresana JS, Ugur HC.

Tumour Biol. 2013 Jun;34(3):1935-47. doi: 10.1007/s13277-013-0738-7. Epub 2013 Mar 22.

PMID:
23519841
16.

Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.

Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT, Mahajan A, Schultz CJ, Erridge S, Baumert B, Hopkins KI, Tzuk-Shina T, Brown PD, Chakravarti A, Curran WJ Jr, Mehta MP.

J Clin Oncol. 2013 Nov 10;31(32):4085-91. doi: 10.1200/JCO.2013.49.6968. Epub 2013 Oct 7.

17.

Is there pseudoprogression in secondary glioblastomas?

Juratli TA, Engellandt K, Lautenschlaeger T, Geiger KD, von Kummer R, Cerhova J, Chakravarti A, Krex D, Schackert G.

Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):1094-9. doi: 10.1016/j.ijrobp.2013.09.036.

18.

Radiotherapy plus concomitant temozolomide in primary gliosarcoma.

Adeberg S, Bernhardt D, Harrabi SB, Diehl C, Koelsche C, Rieken S, Unterberg A, von Deimling A, Debus J.

J Neurooncol. 2016 Jun;128(2):341-8. doi: 10.1007/s11060-016-2117-x. Epub 2016 Mar 30.

PMID:
27025857
19.

MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy.

Melguizo C, Prados J, González B, Ortiz R, Concha A, Alvarez PJ, Madeddu R, Perazzoli G, Oliver JA, López R, Rodríguez-Serrano F, Aránega A.

J Transl Med. 2012 Dec 17;10:250. doi: 10.1186/1479-5876-10-250.

20.

Novel recursive partitioning analysis classification for newly diagnosed glioblastoma: A multi-institutional study highlighting the MGMT promoter methylation and IDH1 gene mutation status.

Wee CW, Kim E, Kim N, Kim IA, Kim TM, Kim YJ, Park CK, Kim JW, Kim CY, Choi SH, Kim JH, Park SH, Choe G, Lee ST, Chang JH, Kim SH, Suh CO, Kim IH.

Radiother Oncol. 2017 Apr;123(1):106-111. doi: 10.1016/j.radonc.2017.02.014. Epub 2017 Mar 13.

PMID:
28302331

Supplemental Content

Support Center